Umhlaza wesibindi ubangela ngo-2026: unyango lwaseTshayina kunye neendleko-izibhedlele ezikufutshane nam 

Umhlaza wesibindi ubangela kwi-2026 ngokuyinhloko iquka izifo ezingapheliyo ze-hepatitis B kunye ne-C, isifo sesibindi esinxulumene notywala, isifo sesibindi esinamafutha angenalo utywala (NAFLD), kunye nokuvezwa kwe-aflatoxins. E-China, oyena nobangela uphambili uhlala ungapheliyo i-Hepatitis B, iqhuba indawo yonyango ekhethekileyo edibanisa unyango oluphezulu lonyango, uqhaqho loqhaqho oluchanekileyo, kunye nezikim ze-inshorensi zesizwe ezinexabiso eliphantsi. Ukuqonda ezi zizathu kubalulekile ekubhaqweni kwangoko kunye nokufikelela kunyango lwamva nje lwezifundo ezininzi olukhoyo kumaziko ezonyango aseTshayina.

IiMbangela zoMhlaza weSibindi eziPhambili kunye neMicimbi yoMngcipheko ngo-2026

I-etiology ye-hepatocellular carcinoma (HCC) iye yavela, kodwa i-hepatitis yentsholongwane iseyeyona nto ihamba phambili kwihlabathi kwaye ngokukodwa e-Asia. Ngo-2026, ukuvumelana kwezonyango kuqaqambisa i-paradigm eguqukayo apho izinto ze-metabolic zinyuka ngokukhawuleza ecaleni kwezizathu zentsholongwane zemveli.

IHepatitis yeNtsholongwane engapheliyo: iNkokeli eZingisayo

Usulelo olungapheliyo ngentsholongwane yeHepatitis B (HBV) yeyona nto ibalulekileyo yomhlaza wesibindi eTshayina. Ngokungafaniyo namazwe aseNtshona apho i-Hepatitis C okanye utywala buxhaphake kakhulu, i-HBV yenza uninzi lwamatyala kummandla. Intsholongwane idibanisa kwi-genome ye-host, ebangela ukuvuvukala okungapheliyo kunye ne-cirrhosis, ekugqibeleni ikhokelela ekuguqulweni okubi.

• IHepatitis B: Inoxanduva malunga ne-70-80% yeemeko ze-HCC e-China. Usulelo olusuka kumama lusiya emntwaneni luhlala luyimbali, nangona iinkqubo zokugonya ziye zalunciphisa usulelo olutsha kwizizukulwana eziselula.
• IHepatitis C: Ngelixa ixhaphake kakhulu kune-HBV eTshayina, ihlala ingunobangela obalulekileyo. Ii-antivirals ezisebenza ngokuthe ngqo (DAAs) ziye zaphucula izinga lokunyanga, kodwa izigulane ezine-cirrhosis esezinzile zihlala zisemngciphekweni nasemva kosulelo lwentsholongwane.

Izikhokelo zamva nje zigxininisa ukuba i-viremia yezinga eliphantsi kwizigulane ezinyangwa nge-nucleos(t)ide analogues isenokubangela ingozi. Uphononongo olupapashwe ekuqaleni kuka-2026 lubonisa ukuba nezigulana ezikunyango lokuqala lwe-antiviral zinokuba ne-viremia ekwinqanaba elisezantsi, nto leyo efuna uqwalaselo oluphaphileyo ukuthintela ukuqhubeka komhlaza.

Ukungasebenzi kakuhle kweMetabolic kunye ne-NAFLD

Isizathu esikhulayo somhlaza wesibindi kwi-2026 yi-Non-Alcoholic Fatty Liver Disease (NAFLD), ngoku ebizwa ngokuba yi-Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Njengoko utshintsho lwendlela yokuphila lwenzeka kulo lonke elaseTshayina, ukutyeba kakhulu kunye nohlobo lwe-2 yeswekile amazinga anyukile.

Olu tshintsho lwemetabolism ludala inani elitsha labantu abaguli abanomhlaza wesibindi abangenayo intsholongwane ye-hepatitis. Inkqubo ibandakanya ukuvutha okungapheliyo kwinqanaba eliphantsi kunye noxinzelelo lwe-oxidative ngaphakathi kwediphozithi yamafutha esibindi. Lo mkhwa ubonisa iipateni zehlabathi kodwa uyakhula ngokukhawuleza kubantu baseTshayina ezidolophini ngenxa yokutshintsha ukutya kunye nendlela yokuphila yokuhlala.

Izifo zesibindi ezinxulumene noTywala kunye neAflatoxins

Ukusela utywala ngokugqithisileyo kusaqhubeka kunegalelo elikhulu. Utywala busebenza ngokubambisana nentsholongwane ye-hepatitis, iphinda-phinda umngcipheko wokuphuhlisa i-HCC. Xa isigulana sine-HBV enganyangekiyo kunye nokusetyenziswa kotywala kakhulu, amathuba okuba nomhlaza akhule ngokukhawuleza xa kuthelekiswa nokuba nomngcipheko wedwa.

Ukongeza, ukuvezwa kokutya kwi-aflatoxins, iikhompawundi eziyityhefu eziveliswa ngumbumba kwiinkozo ezingagcinwanga kakuhle kunye namantongomane, kuhlala kuyinkxalabo kwimimandla ethile. I-Aflatoxin B1 yi-carcinogen enamandla eyenza utshintsho oluthile kwi-TP53 tumor suppressor gene. Ngelixa imimiselo yokhuseleko lokutya iye yaphucuka, lo mba wokusingqongileyo usenegalelo kumthwalo opheleleyo wezifo kwiindawo ezisemaphandleni.

I-China's 2026 Treatment Landscape and Guidelines

I-China iye yavela njengenkokeli yehlabathi kuphando lomhlaza wesibindi kunye nonyango olutsha. Ukukhutshwa kwe Ukuxilongwa koMhlaza weSibindi okusisiseko kunye neziKhokelo zoNyango (uHlelo luka-2026) iphawula isiganeko esibalulekileyo. Ezi zikhokelo zidibanisa ubungqina obuphezulu obuvela kwizilingo zeklinikhi ezikhokelwa yiTshayina, ezinikezela "Isisombululo seSizwe" esilungiselelwe i-epidemiology ethile yommandla.

IziKhokelo eziNtsha zeSizwe (uHlelo luka-2026)

Ikhutshwe ekuqaleni kwe-2026, izikhokelo zesizwe ezihlaziyiweyo zigxininisa izenzo ezisekelwe kubungqina ezisekelwe kwidatha yasekhaya. Ngaphezu kweshumi leminyaka, ezi zikhokelo ziye zavela ukubonisa iimpawu ezizodwa zabaguli baseTshayina, abadla ngokubakho ngamanqanaba esifo ahambele phambili kunye nosulelo olusisiseko lwe-HBV.

Inguqulelo ka-2026 idibanisa ngokucwangcisiweyo iziphumo zophononongo lwezonyango ezikumgangatho ophezulu zakutsha nje, kubandakanywa iziphumo zoqobo ezipapashwe kwiijenali zamazwe ngamazwe ngabaphengululi baseTshayina. Oku kuqinisekisa ukuba iingcebiso zonyango azikho nje ukulungelelaniswa kweeprothokholi zaseNtshona kodwa zilungiselelwe iimeko zofuzo zendawo kunye nokusingqongileyo. Izikhokelo zigxininisa umgaqo wolawulo "lweqela leenkalo ezininzi" (MDT) njengomgangatho wokunyamekela.

Ukudityaniswa kwe-Immunotherapy kunye neTherapy Targeted

Unyango olucwangcisiweyo lomhlaza wesibindi oluphambili luye lwenziwa utshintsho. Uhlaziyo lwenkqubo yohlaziyo lwenkqubo ye-2026 yeKliniki ye-Barcelona yoMhlaza weSibindi (BCLC), etolikwa ziingcali eziphambili zaseTshayina, iqinisa indawo yonyango lokudibanisa amajoni omzimba njengomgangatho wokuqala wesifo seSigaba C.

• Umgangatho WokuQala: Ukuhlanganiswa kwe-immune checkpoint inhibitors (njenge-PD-1 monoclonal antibodies) kunye ne-tyrosine kinase inhibitors (njenge-sorafenib okanye i-lenvatinib) ngoku imilinganiselo yegolide.
• Imithetho ethile: Idatha yeklinikhi isekela ukusetyenziswa kwe-PD-1 inhibitors edibeneyo ne-lenvatinib okanye i-sorafenib, ebonisa ukusinda okupheleleyo xa kuthelekiswa ne-monotherapy.

Uphando oluthiwe thaca ekuqaleni kuka-2026 luqaqambisa ukusebenza kwezi ndibaniselwano nakwizigulana ezinoMntwana-Pugh B wesibindi, iqela ebekade lithathwa njengelibuthathaka kakhulu kunyango lwenkqubo enobundlobongela. Oku kwandiswa kokufaneleka konyango kunika ithemba kuluntu olubanzi lwezigulane.

I-Neoadjuvant kunye neConversion Therapy Consensus

Impumelelo enkulu kwihepatology yaseTshayina kukwenziwa ngokusesikweni kwe-neoadjuvant kunye nezicwangciso zonyango loguqulo. I Imvumelwano yeNgcali yaseTshayina kwi-Neoadjuvant kunye noTshintsho loNyango lwe-Hepatocellular Carcinoma (uhlaziyo lwe-2024/2026), epapashwe kwiijenali zenqanaba eliphezulu njenge Umhlaza Wesibindi, ibonelela ngemephu yendlela yokuguqula i-tumor engabonakaliyo ibe yi-rectable.

Njengoko i-70-80% yezigulane zaseTshayina zifunyaniswa kumanqanaba aphakathi okanye aphezulu apho utyando lungenakwenzeka ekuqaleni, unyango lokuguqulwa lubalulekile. Le ndlela isebenzisa unyango lwe-systemic ukunciphisa amathumba, okuvumela ukunyangwa okulandelayo. Imvumelwano ichaza imigaqo ecacileyo yokukhethwa kwesigulane, imijikelezo yonyango, kunye nexesha lotyando, ukunciphisa izinga lokuphindaphinda elifikelele kwi-70% kwiminyaka emihlanu emva kokuhlinzwa.

UbuGcisa obuPhezulu kunye nobuChwephesha bokungenelela

Utyando luhlala lukuphela kwendlela enokunyanga umhlaza wesibindi okwinqanaba lokuqala. Nangona kunjalo, inkcazo "ye-resectable" yandisiwe ngenxa yovavanyo olungcono lwangaphambili kunye nonyango olongezelelweyo. Amaziko aphambili e-China asebenzisa itekhnoloji ye-cutting-edge ukunyusa iziphumo.

Ukuchithwa okuchanekileyo kunye noTshintsho lwesibindi

Amaziko onyango amakhulu, anje ngeHepatobiliary kunye nePancreatic Centre kwisibhedlele saseBeijing Tsinghua Changgung, asebenzisa iindlela ezichanekileyo zonyango. Oogqirha abanje nge-Academician Dong Jiahong amaqela akhokelayo enza uqhaqho oluntsonkothileyo ngokulahleka kwegazi okuncinci kunye namaxesha okubuyisela ngokukhawuleza.

Ukutshintshwa kwesibindi kugcinelwe izigulane ezihlangabezana neendlela ezithile (ezifana ne-Hangzhou Criteria okanye i-UCSF criteria), ngamanye amaxesha iquka ngakumbi kuneendlela eziqhelekileyo zeMilan ukulungiselela umthamo ophezulu weemeko ezinxulumene ne-HBV e-China. Ukudityaniswa kwe-antiviral prophylaxis post-transplant kuye kwanciphisa kakhulu izinga lokuphindaphinda kubantu abafumana i-HBV-positive.

I-Radiotherapy entsha: I-Lattice kunye ne-SBRT

Unyango ngemitha luye lwavela kumlinganiselo wokudambisa ukuya kwindlela yonyango. Uhlaziyo lwe-2026 BCLC lubandakanya ngokucacileyo i-Stereotactic Body Radiation Therapy (SBRT) kunye ne-Transarterial Radioembolization (TARE) njengeendlela zonyango ezinzulu kwiSigaba 0/A izigulane ezingabaviwa botyando okanye ukukhutshwa.

Abaphandi baseTshayina bangoovulindlela kwi-"Lattice Radiotherapy" yamathumba amakhulu angenakucocwa (≥10 cm). Obu buchwephesha buhambisa iidosi eziphezulu kakhulu zemitha yemitha kwiindawo ezithile ngaphakathi kwithumba ngelixa ugcina izicubu ezisempilweni ezingqongileyo. Idatha yokuqala yeklinikhi eboniswe kwiNtlanganiso yoNyaka ka-2026 ye-ASCO icebisa ukhuseleko oluthembisayo kunye neeprofayili ezisebenzayo xa zidityaniswa nonyango lwenkqubo.

I-Inventional Radiology Advances

I-Transarterial Chemoembolization (TACE) ihlala ililitye lembombo kwi-intermediate-stage (BCLC B) isifo. Nangona kunjalo, izikhokelo zika-2026 zilumkisa ngokuchasene nendibaniselwano yesiqhelo ye-TACE kunye nonyango lwenkqubo ngaphandle kwezilingo zeklinikhi, kuphawula ukuba ubungqina bangoku abuyixhasi jikelele le ndlela kuwo onke amacandelwana.

Iiarhente ezitsha ze-embolic kunye namaso e-eluting drug-eluting zisetyenziselwa ukuphucula impendulo yethumba. Ngaphezu koko, ingcamango "yokufuduka kwesigaba sonyango" ivumela oogqirha ukuba batshintshe ngokuguquguqukayo phakathi kwe-TACE, unyango lwenkqubo, kunye notyando olusekelwe kwimpendulo ye-tumor, ukuqinisekisa ukuba izigulane zihlala zifumana ukungenelela okufanelekileyo.

Ukufumana izibhedlele kunye neengcali ezikufutshane nawe eTshayina

Ukufikelela kukhathalelo olukumgangatho ophezulu kufuna ukwazi ukuba aphi amaziko ogqweso. I-China inamaziko amaninzi akumgangatho wehlabathi we-hepatobiliary axhotyiswe ngetekhnoloji yamva nje kunye namaqela ahlukeneyo.

Amaziko aphezulu e-Hepatobiliary

Isibhedlele saseBeijing Tsinghua Changgung: Ikhokelwa nguDong Jiahong, eli ziko lidume ngotyando oluntsonkothileyo lwesibindi kunye nokufakelwa kwamalungu. Iqela libandakanya iingcali ezifana noDkt. Lu Qian kunye noDkt Xiang Canhong, ojongene nokutshatyalaliswa okuchanekileyo kunye nolawulo lwe-multidisciplinary. Banikezela ngeeklinikhi ezikhethekileyo kwiimeko ezinzima, kubandakanywa nezo zihlaselwa yi-vascular invasion.

Isibhedlele saseFudan iYunivesithi iZhongshan (iShanghai): I-hub yophando lomhlaza wesibindi kunye nesicelo seklinikhi. Ngaphantsi kwesikhokelo seengcali ezifana noNjingalwazi uGao Qiang, esi sibhedlele sisixhobo sokubumba izikhokelo zelizwe kunye nokuphumeza isakhelo esitsha sokwenza izigqibo ze-CUSE. Iyinkokeli ekudibaniseni i-radiology yongenelelo kunye nonyango lwenkqubo.

Isibhedlele saseZhongnan kwiYunivesithi yaseWuhan: Yaziwa ngokuhambela phambili kwayo kwiradiotherapy kunye ne-chemoradiotherapy yethambo kunye nezicubu ezithambileyo zamathumba kunye ne-hepatobiliary cancers. Ukungeniswa kwabo mva nje kwi-ASCO kuqaqambisa iinguqulelo ezintsha kwiradiotherapy kunye nezifundo zohlengahlengiso lwe-metabolic.

Indlela yokufikelela kuKhathalelo

Uninzi lwezibhedlele ezikumgangatho ophezulu eTshayina zisebenza ngenkqubo yokuqeshwa. Izigulana zinokubhukisha ukubonisana ngeeakhawunti ezisemthethweni zesibhedlele ze-WeChat, ii-apps ezizinikeleyo, okanye iifowuni zomnxeba. Kwizigulane zamazwe ngamazwe okanye abo basuka kumaphondo akude, amaziko amaninzi anikezela ukubonisana kwe-telemedicine yokuqala ukuphonononga imaging kunye ne-pathology ngaphambi kokuhamba.

• Inyathelo 1: Hlanganisa zonke iirekhodi zonyango, kubandakanywa i-CT / MRI scans (kwi-DICOM CD), iingxelo ze-pathology, kunye neziphumo zovavanyo lwegazi (ingakumbi i-AFP kunye nokusebenza kwesibindi).
• Inyathelo lesi-2: Qhagamshelana nesebe lezonyango lesibhedlele lamazwe ngamazwe okanye usebenzise iqonga ledijithali elisemthethweni ukubhalisa ingcali kwi-Hepatobiliary Surgery okanye i-Hepatology.
• Inyathelo lesi-3: Yiya kwikliniki yeqela leeNgxoxo ezininzi (MDT) ukuba ikhona. Oku kuqinisekisa ukuba oogqirha botyando, i-oncologists, kunye nee-radiologists baphonononga ityala kunye ukuze benze isicwangciso esilungileyo.

Iindleko zonyango kunye ne-Inshurensi ngo-2026

Iindleko zonyango lomhlaza wesibindi e-China zihluka kakhulu ngokuxhomekeke kwinqanaba lesi sifo, unyango olukhethiweyo, kunye nenqanaba lesibhedlele. Nangona kunjalo, inkqubo yokhuseleko lwezempilo yelizwe eyomeleleyo yenze ukuba unyango oluphezulu lufikeleleke ngakumbi.

Ukwahlulwa kweendleko zonyango

Uqhaqho ngokutsha: Iindleko ze-hepatectomy eqhelekileyo zivela kwi-40,000 ukuya kwi-80,000 RMB (i-$ 5,500 - i-$ 11,000 USD). Utyando olunzima olubandakanya ukwakhiwa kwakhona kwemithambo okanye iindlela ze-laparoscopic / robotic zingabiza phakathi kwe-80,000 kunye ne-120,000 RMB.

UTshintsho lwesibindi: Olu lolona khetho lubiza kakhulu, ngokuqhelekileyo ukusuka kwi-400,000 ukuya kwi-600,000 RMB (i-$ 55,000 - i-$ 83,000 USD). Oku kubandakanya utyando, iintlawulo zokufumana amalungu, kunye nokulaliswa esibhedlele kokuqala. Amayeza exesha elide e-immunosuppressive yongeza kwiindleko eziqhubekayo.

Unyango Lwenkqubo: Phambi kothethathethwano lwakutsha nje, amayeza ekujoliswe kuwo kunye nonyango lokuzikhusela komzimba lwalubiza kakhulu. Kwi-2026, ngenxa ye-volume-based procurement (VBP) kazwelonke kunye nokufakwa kwi-National Reimbursement Drug List (NRDL), iindleko ziye zehla kakhulu. Iindleko zenyanga ze-PD-1 inhibitors kunye ne-TKIs ngoku zinokuphantsi njenge-2,000 ukuya kwi-5,000 RMB (i-$ 280 - i-$ 700 USD) kwizigulane ezikhuselweyo.

Imigaqo-nkqubo yokuBuyiselwa kwe-inshorensi

I-Inshurensi yezoNyango eSiseko yaseTshayina (BMI) ibandakanya inxalenye ebalulekileyo yonyango lomhlaza wesibindi. Izinga lokhuseleko lweendleko zezigulana ezilaliswa kwizibhedlele zikawonke-wonke likholisa ukuba ngaphezulu kwama-70% kubasebenzi basezidolophini kwaye libe ngaphantsi kancinane kubahlali basemaphandleni, ngokuxhomekeke kwingingqi.

• Uluhlu lwembuyekezo yeSizwe yeziyobisi (NRDL): Iindibaniselwano ezininzi zodidi lokuqala lwe-immunotherapy (umzekelo, i-camrelizumab, i-sintilimab edityaniswe ne-apatinib okanye i-rivoceranib) ngoku iyabuyiswa. Olu tshintsho lomgaqo-nkqubo lube yinto etshintshayo, nto leyo eyenza ukuba unyango olusemgangathweni lufikeleleke kubantu abaninzi.
• I-Inshurensi yezigulo eziBalulekileyo: Izikim ze-inshorensi ezongezelelweyo zibonelela ngokhuseleko olongezelelekileyo lwenkcitho yempilo eyingozi, ngakumbi ukunciphisa iindleko eziphuma epokothweni kwiintsapho.

Kwizigulane zamazwe ngamazwe ezingakhuselwanga, iindleko ziya kuba phezulu njengoko zihlawula ixabiso elipheleleyo loluhlu. Nangona kunjalo, nangexabiso elipheleleyo, unyango e-China lunexabiso elithe kratya xa lithelekiswa ne-US okanye iYurophu, ngaphandle kokunciphisa umgangatho wokunyamekela okanye ukufikelela kumachiza akutshanje.

Uhlahlelo oluThethayo loBuchule boNyango

Ukukhetha unyango olufanelekileyo kuxhomekeke kwinqanaba lethumba, ukusebenza kwesibindi, kunye nesimo sokusebenza kwesigulane. Le theyibhile ilandelayo ithelekisa iindlela eziphambili ezikhoyo eTshayina ngo-2026.

Isakhelo sokuThatha iSigqibo se-CUSE

Inkqubela phambili ephawulekayo ngo-2026 kukwamkelwa kwesakhelo se-CUSE ekuthathweni kwezigqibo zeklinikhi. Ecetywayo kwizikhokelo ze-BCLC ezihlaziyiweyo kwaye zixhaswa ziingcali zaseTshayina, le modeli ihamba ngaphaya kwe-algorithms engqongqo ukuya kwindlela egxile kwisigulane.

Ukuqonda Imilinganiselo Emine

Isakhelo se-CUSE sivavanya imilinganiselo emine ebalulekileyo ukukhokela iQela leeNdlela ezininzi (MDT):

• Ukuntsokotha: Ivuma ubume be-multifactorial yesi sifo, ithathela ingqalelo i-tumor biology, i-physiology yesibindi, kunye ne-comorbidities ngaxeshanye.
• Ukungaqiniseki: Ijongana nengqikelelo entsonkothileyo kunye nobume obuphindaphindiweyo bobungqina bezonyango. Ivumela ukuguquguquka njengoko idatha entsha ivela ngexesha lonyango.
• Ukuthobela: Uyayibona iintlukwano zabantu ngabanye kwindlela oogqirha kunye nezigulana eziyibona ngayo ingozi kunye neenzuzo. Ibandakanya ukhetho lwesigulane kunye nemilinganiselo.
• Imiba yoMvakalelo: Uthathela ingqalelo impembelelo yengqondo, amava exesha elidlulileyo, kunye neenkolelo zobuqu zesigulana kunye neqela lokhathalelo.

Esi sikhokelo siqinisekisa ukuba izicwangciso zonyango aziphelelanga nje ngokweenkcukacha-manani kodwa ziyakwazi ukusebenza kwaye zamkelekile kwisigulana ngasinye. Kubaluleke kakhulu kwiimeko ezinqamlekileyo apho kukho iindlela ezininzi zonyango, ezinceda ukukhangela urhwebo phakathi kobundlongondlongo kunye nomgangatho wobomi.

Uphando olusakhulayo kunye nezikhokelo zexesha elizayo

Amaziko ophando aseTshayina anegalelo elibonakalayo ekuqondweni kwehlabathi lomhlaza wesibindi. Izifundo zakutsha nje ezithiwe thaca kwiinkomfa ezinkulu ezifana ne-ASCO 2026 zibalaselisa iindlela ezininzi ezithembisayo.

Ukuhlengahlengiswa kweMetabolic kunye neFerroptosis

Abaphandi bafumanisa ukuba utshintsho lwe-metabolic luqhuba njani ukuqhubela phambili komhlaza. Uphononongo oluvela kwiSibhedlele saseWuhan Zhongnan lubonise ukuba i-metabolites efana ne-alpha-ketoglutarate inokubangela i-ferroptosis (ukufa okuxhomekeke kwintsimbi), iphucula ubuntununtunu bomhlaza we-colorectal kunye nesibindi kwimitha. Oku kuvula iingcango kunyango oludityanisiweyo olusebenzisa i-tumor metabolism ukunyusa ukusebenza konyango lwesintu.

Iintsholongwane ze-Oncolytic kunye neNoveli Immunotherapies

I-Innovative immunotherapies iyakhula. Ulingo lwezonyango luphanda iintsholongwane ze-oncolytic (ezifana ne-OH2) ezilawulwa ngokuthe ngqo kumathumba, zilandelwa yinkqubo ye-immune checkpoint blockade. Idatha yesigaba sakwangoko icebisa ukuba le ndlela ilandelelana inokuvuselela impendulo eyomeleleyo yokulwa ne-tumor, nakwizithumba "ezibandayo" ezingaphenduliyo kunyango lomzimba lodwa.

Ukujongana ne-Colorectal Liver Metastases

Ngelixa i-HCC iyona nto iphambili ekugxilwe kuyo, ukunyuka komhlaza we-colorectal (CRC) e-China kuye kwazisa ingqalelo kwi-Colorectal Liver Metastases (CRLM). Nge-CRC ibe ngowona mhlaza uxhaphakileyo e-China, izicwangciso ezikhethekileyo ze-CRLM zibalulekile. Unyango lwasekhaya oluluqilima kunye nolawulo olubanzi lubonisa ukwandisa ukusinda kwezi zigulana, kunye neerejistri ezibonisa ukuba isibindi sesona sayithi sixhaphakileyo se-metastasis ye-CRC.

Imibuzo Ebuzwa Rhoqo malunga noMhlaza Wesibindi eTshayina

Ngaba umhlaza wesibindi uyanyangeka ngo-2026?

Ewe, umhlaza wesibindi okwinqanaba lokuqala unokunyangeka ngotyando, utyando lwesibindi, okanye ukukhutshwa. Kwizigaba eziphambili, ngelixa "ukunyanga" kunqabile, injongo kukulawula ixesha elide kunye nokwandiswa kokusinda. Ukufika konyango olusebenzayo lwe-immuno-combination iye yaguqula i-HCC ephucukileyo ibe yimeko elawulekayo engapheliyo kwizigulana ezininzi, kunye namazinga okuphila aphakathi xa kuthelekiswa neminyaka edlulileyo.

Luxabisa malini unyango lomhlaza wesibindi eTshayina?

Iindleko ziyahluka ngokubanzi. Utyando olusisiseko lunokubiza malunga ne-6,000 ye-USD, ngelixa ukufakelwa okuntsonkothileyo kunokugqithisa i-80,000 USD. Nangona kunjalo, kubemi baseTshayina abane-inshurensi, iindleko eziphuma epokothweni ziphantsi kakhulu ngenxa yemigaqo-nkqubo yembuyekezo. Amachiza aphucukileyo afana ne-PD-1 inhibitors ngoku ayafikeleleka, axabisa amakhulu ambalwa eedola ngenyanga emva kwe-inshurensi, nto leyo eyenza ukuba unyango olukumgangatho wehlabathi lufikeleleke.

Zeziphi izizathu eziphambili zomhlaza wesibindi eTshayina?

Oyena nobangela lusulelo lwe-Hepatitis B olungapheliyo, olubalelwa kuninzi lwamatyala. Ezinye izizathu ezibalulekileyo zibandakanya i-Hepatitis C, ukusetyenziswa kotywala ngokugqithiseleyo, kunye nokunyuka, isifo sesibindi esingenalo utywala (NAFLD) esiqhutywa kukutyeba kunye nesifo sikashukela. Ukuvezwa kwe-Aflatoxin kuhlala kungumngcipheko kwimimandla ethile.

Ndingalufumana unyango e-China njengomntu wangaphandle?

Ngokuqinisekileyo. Izibhedlele ezikhulu ezifana neBeijing Tsinghua Changgung Hospital kunye neFudan Zhongshan Hospital zinamasebe ezizwe ngezizwe abonelela abaguli bangaphandle. Banikezela ngabaququzeleli abathetha isiNgesi, uncedo ngee-visa, kunye nezicwangciso zonyango ezilungiselelweyo. Ngelixa ukhuseleko lwe-inshorensi lunokwahluka, umgangatho wokhathalelo uhambelana nemigangatho yehlabathi, rhoqo ngexabiso eliphantsi lilonke kunamazwe aseNtshona.

Ukuqukumbela

Ukuqonda umhlaza wesibindi ubangela linyathelo lokuqala ekuthinteleni nasekubhaqweni kwangethuba, ngakumbi kwimimandla esemngciphekweni omkhulu njengeTshayina apho iHepatitis B igquba khona. Ngo-2026, imeko yonyango lomhlaza wesibindi e-China ibonakaliswa kukwenziwa kwezinto ezikhawulezayo, uhlaziyo lwesikhokelo esingqongqo, kunye nokuzinikela okuqinileyo ekwenzeni unyango oluphezulu lufikeleleke. Ukususela ekwamkelweni okuxhaphakileyo kwerejimeni zokudibanisa amajoni omzimba ukuya ekucokiseni iindlela zotyando kunye nokuphunyezwa kwezicwangciso zezigqibo ezigxile kwisigulane njenge-CUSE, i-China ibeka i-benchmarks entsha kukhathalelo lwe-hepatobiliary.

Izigulane namhlanje zineendlela ezininzi zokukhetha kunangaphambili. Nokuba ngotyando lokunyanga, iradiotherapy echanekileyo, okanye unyango lwenkqubo yokwandisa ubomi, ukudityaniswa kobungcali bezifundo ezininzi kuqinisekisa ukuba isigulane ngasinye sifumana isicwangciso esilungiselelweyo. Ngenkxaso yemigaqo-nkqubo ye-inshorensi yelizwe yokunciphisa imiqobo yezemali, indlela esuka ekuxilongeni ukuya ekusindeni icacile kwaye inethemba. Kuye nabani na ofuna unyango, amaziko akumgangatho wehlabathi kunye namaqela eengcaphephe eTshayina abonelela ngethemba, edibanisa isayensi enovelwano kunye novelwano ukulwa esi sifo soyikekayo.